Pacira(US:PCRX)2026-01-08 21:02Financial Performance - Preliminary unaudited total revenue for 2025 was $726.4 million, up from $701.0 million in 2024, representing a year-over-year increase of approximately 3.5%[1] - Full-year EXPAREL net product sales reached $575.1 million in 2025, compared to $549.0 million in 2024, reflecting a volume growth of 6%[4] - Fourth quarter EXPAREL net product sales were $155.8 million, an increase from $147.7 million in the same quarter of 2024, marking a volume growth of 7%[5] - Full-year ZILRETTA net product sales were $116.6 million in 2025, down from $118.1 million in 2024[12] - Full-year iovera° net product sales increased to $24.2 million in 2025, compared to $22.8 million in 2024[12] Share Repurchase and Cost Management - The company repurchased 2.0 million shares of common stock for $50.0 million during the fourth quarter, with $150.0 million remaining on its share repurchase authorization[7] - The company anticipates a reduction in force by July 2025, which is expected to yield cost savings[30] Strategic Initiatives - Pacira's strategic priorities, termed '5x30', focus on sustainable long-term growth and operational progress[2] - The company is focused on the commercialization of EXPAREL, ZILRETTA, and iovera°, with plans to expand their use to additional indications[32] - The success of EXPAREL, ZILRETTA, and iovera° is contingent on the timing and success of FDA supplemental New Drug Applications and EMA Marketing Authorization Applications[32] - The company is evaluating and developing additional product candidates utilizing proprietary multivesicular liposome (pMVL) drug delivery technology[32] Pipeline Development - The company is advancing its pipeline with PCRX-201, a gene therapy for knee osteoarthritis, currently in Phase 2 clinical development[26] - The company has identified numerous cytokines for potential locally administered genetic therapies using its high-capacity adenovirus vector platform[29] Gene Therapy Technology - The HCAd vector is significantly more efficient at delivering genes into cells compared to AAV vectors, allowing for effective treatment with smaller doses[31] - The HCAd platform can carry up to 30,000 base pairs of DNA, enabling gene therapy for multiple or larger genes[31] - Genetic medicines based on the HCAd platform can be administered locally and allow for potential redosing at therapeutically appropriate intervals[31] - The efficient delivery of genes means that thousands of doses can be produced in a single batch, leading to a commercially attractive cost of goods profile[31] Future Outlook and Risks - Pacira expects to report complete financial results for the fourth quarter and full-year 2025 in the first quarter of 2026[6] - Future growth potential and financial results are subject to various risks, including integration challenges from the acquisition of GQ Bio Therapeutics GmbH[30] - Actual results may differ materially from forward-looking statements due to known and unknown risks and uncertainties[33]